Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews

Oct 07 2016

• By Derrick Gingery

Related Content

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

<em>Neupogen</em> Off-Label Use Complicates Data Extrapolation For Sandoz’s Biosimilar

Jan 19 2015

Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure

May 02 2016

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Oct 06 2016

Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Oct 05 2016

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Aug 31 2016

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

Oct 06 2016

Related Companies

Celltrion, Inc.

Biogen, Inc.

Genentech, Inc.

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Pfizer Inc.

Novartis AG

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Additional Topics

United States Biosimilars Research & Development Drug Review Review Pathway BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window